Señales en vivo de 196170.KQ | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 02:30):

Stats
Volumen de hoy	973 434
Volumen promedio	1.93M
Capitalización de mercado	9 389.49B
EPS	KRW0 ( 2024-03-17 )
Próxima fecha de ganancias	( KRW0 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW314.81 (0.18%)

Volumen Correlación

Largo: -0.45 (neutral)

Corto: 0.35 (neutral)

Signal:(46.488) Neutral

ALTEOGEN Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ALTEOGEN Inc. Correlación - Moneda/Commodity

-0.44
( neutral )

-0.53
( weak negative )

0.60
( weak )

-0.66
( moderate negative )

-0.73
( moderate negative )

ALTEOGEN Inc. Finanzas

Annual	2023
Ingresos:	KRW96.52B
Beneficio Bruto:	KRW82.23B (85.19 %)
EPS:	KRW-65.27

FY	2023
Ingresos:	KRW96.52B
Beneficio Bruto:	KRW82.23B (85.19 %)
EPS:	KRW-65.27

FY	2022
Ingresos:	KRW28.81B
Beneficio Bruto:	KRW9.41B (32.67 %)
EPS:	KRW-158.85

Financial Reports:

No articles found.

ALTEOGEN Inc.

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; and ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology. The company has a strategic alliance with Kissei Pharmaceutical to develop Aflibercept that has completed pre-clinical trial; and Cristalia for the development of Trastuzumab, which is in the Phase II clinical trial for the treatment of breast cancer. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.